Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at https://www.cytokinetics.com. The webcast replay will be ...
Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...
Middle aged and older adults who are hospitalized for severe infections were more than twice as likely to develop heart failure in the future, a new study shows. Authors say that’s why it’s so ...
The full lineup of late-breaking clinical science to be presented at THT 2025: Technology and Heart Failure Therapeutics is now available online. Organized by the Cardiovascular Research Foundation® ...
Patients with rheumatoid arthritis are associated with an increased risk for heart failure, particularly heart failure with preserved ejection fraction.
Bayer seeks European marketing approval for use of finerenone in adult patients with HF with a left ventricular ejection fraction (LVEF) of =40%: Berlin Tuesday, February 4, 2025, ...
Researchers discovered that ALPK2, a heart-specific enzyme, may protect against HFpEF by activating TPM1 in heart muscle ...
Tectonic Therapeutic said the findings support the design and population for Phase 2 APEX trial, which will test TX45 in ...
What is ALPK2, and how can it help treat heart failure? Researchers have found that this heart-specific enzyme may prevent ...
In particular, severe infections tripled the risk of heart failure with preserved ejection fraction (HFpEF), which occurs ...
Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...
Finerenone treatment vs placebo was associated with a reduced risk for new-onset diabetes by 24% among patients with HFmrEF or HFpEF.